No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Celltrion Submits BLA for Interchangeable Omalizumab (Xolair®) Biosimilar
Celltrion announced that it has submitted an abbreviated Biologics License Application (A-BLA) in the US for approval of CT-P39, as interchangeable biosimilar to Genentech’s Xolair® (omalizumab). Celltrion’s application seeks approval for all Xolair® indications, as...